Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]
Discontinued
Reference number: GID-TA10151
NICE has decided to reschedule this appraisal to align with the company’s latest regulatory expectations.
The first committee discussion and will now take place on 22 May 2018.